Key Insights

Highlights

Success Rate

83% trial completion

Published Results

376 trials with published results (23%)

Research Maturity

1053 completed trials (64% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

13.1%

217 terminated out of 1656 trials

Success Rate

82.9%

-3.6% vs benchmark

Late-Stage Pipeline

9%

154 trials in Phase 3/4

Results Transparency

36%

376 of 1053 completed with results

Key Signals

376 with results83% success217 terminated

Data Visualizations

Phase Distribution

1,395Total
Not Applicable (180)
Early P 1 (13)
P 1 (487)
P 2 (561)
P 3 (141)
P 4 (13)

Trial Status

Completed1,053
Terminated217
Unknown153
Recruiting99
Withdrawn68
Active Not Recruiting41

Trial Success Rate

82.9%

Benchmark: 86.5%

Based on 1053 completed trials

Clinical Trials (1656)

Showing 20 of 20 trials
NCT07524530Phase 2Not Yet Recruiting

Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers

NCT07328516Enrolling By Invitation

Natural History Study of Early Life Exposures in Agriculture (ELEA)

NCT02012699Recruiting

Integrated Cancer Repository for Cancer Research

NCT07566377Phase 2Recruiting

Cord Blood Transplantation in Children and Young Adults With Blood Cancer

NCT00339963CompletedPrimary

Genome Expression in Lymphoma, Leukemia and Multiple Myeloma

NCT05237986Recruiting

Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy

NCT01139476Completed

Specimen Collection for Agricultural Health Study Cohort Pesticide Exposure Study

NCT03226704Enrolling By InvitationPrimary

Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing

NCT06578247Phase 3RecruitingPrimary

Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

NCT05536349Phase 2RecruitingPrimary

Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

NCT03058588RecruitingPrimary

Next Generation Sequencing (NGS) in Familial Acute Myeloid Leukemia and Myelodisplastic Syndromes

NCT00342888CompletedPrimary

Case-Control Study of Pesticides and Childhood Leukemia

NCT07556757Phase 1Recruiting

A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia

NCT00558519Phase 2CompletedPrimary

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

NCT01500733Phase 2Active Not RecruitingPrimary

PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT07374315Not ApplicableNot Yet RecruitingPrimary

Weight Gain in Pediatric Leukemia Survivors

NCT05268003Phase 2Terminated

A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia

NCT01044069Phase 1Active Not RecruitingPrimary

Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19

NCT03601442Unknown

Managed Access Programs for CTL019, Tisagenlecleucel

NCT05645718Phase 2RecruitingPrimary

Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

Scroll to load more

Research Network

Activity Timeline